Zacks Investment Research·Aug 11, 2026
CryoPort (CYRX) Upgraded to Buy: Here's WhyCryoPort (CYRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Cryoport appears to be in a high-investment phase following its 2025 acquisition, with capital expenditures surging to 39.0% of revenue in 2026Q2, but this has yet to translate into a path to profitability. The company's core operations are structurally unprof...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.20-3.5% vs -$0.19 | $49M+1.6% vs $48M |
Q2 2026 May 4, 2026 | -$0.23-15.0% vs -$0.20 | $48M+6.5% vs $45M |
Q2 2026 Mar 3, 2026 | -$0.21-10.5% vs -$0.19 | $45M+6.1% vs $43M |
Q4 2025 Nov 4, 2025 | -$0.18+21.7% vs -$0.23 | $44M+7.4% vs $41M |
CryoPort (CYRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Cryoport, Inc. (CYRX) Q2 2026 Earnings Call Transcript
CryoPort NASDAQ: CYRX reported second-quarter 2026 revenue of $49 million and said it reached positive adjusted EBITDA from continuing operations, while reaffirming its full-year revenue outlook of $192 million to $196 million.
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.2 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.29 per share a year ago.
Benchmark CYRX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Cryoport, Inc. (CYRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $17.49 | $881.54M | 12.49 | -24.47% | 44.44% | 17.31% | — | |
| $67.49 | $6B | -84.36 | 1031.18% | 30.74% | 149.64% | — | |
| $15.06 | $476.27M | -4.33 | 0.84% | -11.37% | -320.56% | — | |
| $3.70 | $138.05M | -2.52 | -1.71% | -13.45% | — | — | |
| $15.53 | $1.21B | -2.31 | 1.53% | -0.44% | -0.69% | — | |
| $95.81 | $81.39B | 14.61 | -2.46% | 5.08% | 29.02% | — |
Cryoport, Inc. (CYRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Cryoport, Inc. (CYRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 9, 2026·SEC
May 4, 2026·SEC
Get notified when CYRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Cryoport, Inc. (CYRX) stock FAQ — growth, dividends, profitability & financials explained
Cryoport, Inc. (CYRX) reported $186.5M in revenue for fiscal year 2025. This represents a 68593% increase from $0.3M in 2003.
Cryoport, Inc. (CYRX) saw revenue decline by 24.5% over the past year.
Cryoport, Inc. (CYRX) reported a net loss of $36.3M for fiscal year 2025.
Cryoport, Inc. (CYRX) has a return on equity (ROE) of 17.3%. This is reasonable for most industries.
Cryoport, Inc. (CYRX) had negative free cash flow of $26.9M in fiscal year 2025, likely due to heavy capital investments.
